U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

About this Database | Back to Search Page

Guidances | CFR

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with D

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
138007 Q2 2022 DIBUTYL SEBACATE ORAL CAPSULE 20mg Correction
138008 Q3 2022 DIBUTYL SEBACATE ORAL CAPSULE 15mg Correction
138094 Q3 2022 D&C RED NO. 30 ALUMINUM LAKE ORAL TABLET, COATED PARTICLES 0.80 mg Deletion
138095 Q3 2022 D&C RED NO. 33 ORAL CAPSULE, DELAYED RELEASE NA Deletion
138096 Q3 2022 DIETHYL PHTHALATE ORAL CAPSULE, DELAYED RELEASE PELLETS 8.89 mg 9mg Deletion
138097 Q3 2022 DYE FDC BLUE NO. 40 HT LAKE ORAL CAPSULE 0.16 mg Deletion
138098 Q3 2022 DYE FDC BLUE NO. 40 HT LAKE ORAL TABLET 0.23 mg Deletion
138110 Q3 2022 DEXTRIN ORAL SOLUTION 20.00 mg/ 5.00 ml 480mg Deletion
138217 Q2 2022 D&C RED NO. 27 ORAL TABLET, DELAYED RELEASE 0.70 mg MDE Replacement
138218 Q3 2022 D&C RED NO. 27 ORAL TABLET, DELAYED RELEASE 1mg MDE Replacement
138219 Q2 2022 DEXTROSE MONOHYDRATE NASAL SPRAY, METERED 5.00 mg MDE Replacement
138220 Q3 2022 DEXTROSE MONOHYDRATE NASAL SPRAY, METERED 20mg MDE Replacement
138221 Q2 2022 DIACETYLATED MONOGLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 2.37 mg MDE Replacement
138222 Q3 2022 DIACETYLATED MONOGLYCERIDES ORAL CAPSULE, EXTENDED RELEASE 8mg MDE Replacement
138223 Q2 2022 DIBASIC POTASSIUM PHOSPHATE ORAL SUSPENSION 1.00 mg/ 1.00 ml MDE Replacement
138224 Q3 2022 DIBASIC POTASSIUM PHOSPHATE ORAL SUSPENSION 24mg MDE Replacement
138225 Q2 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER ORAL SUSPENSION 85.00 mg/ 5.00 ml MDE Replacement
138226 Q3 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER ORAL SUSPENSION 255mg MDE Replacement
138227 Q2 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER ORAL TABLET, DELAYED RELEASE 2.16 mg MDE Replacement
138228 Q3 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER ORAL TABLET, DELAYED RELEASE 4mg MDE Replacement
138229 Q2 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER TRANSDERMAL SYSTEM 18.00 mg MDE Replacement
138230 Q3 2022 DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER TRANSDERMAL SYSTEM 18mg MDE Replacement
138231 Q2 2022 DYE ORANGE PB-2148 ORAL TABLET 0.16 mg MDE Replacement
138232 Q3 2022 DYE ORANGE PB-2148 ORAL TABLET 1mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 1, 2022
Database Last Updated: July 18, 2022

Back to Top